All In Biotech

Drug Trial Radar · NCT07724132

An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

Alzheimer's Disease- Systematic Multi-Arm Adaptive Randomised Trial

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Jul 24, 2026

Primary completion

Mar 2031

Study completion Mar 2031

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Health Research, United Kingdom; Imperial College London; UK Dementia Research Institute Ltd; Alzheimers Research UK
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease in a population representative of people with Alzheimer's disease in the UK.

Conditions

  • Alzheimer's Disease (AD)
  • Mild Cognitive Impairment Due to Alzheimer's Disease
  • Alzheimer Disease Dementia

Interventions

  • PlaceboDrug

    Oral capsule matching active treatments

  • AtomoxetineDrug

    Atomoxetine (Oral, up to 100 mg/day)

  • Metformin 1000 mg Oral TabletDrug

    Metformin IR Oral, up to 2000 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scoreTime frame: Baseline to 18 months
  2. Change in Amsterdam Instrumental Activities of Daily Living Questionnaire - Short Version (A-IADL-Q-SV) scoreTime frame: Baseline to 18 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Windsor Research Unit

    Cambridge, United Kingdom · Recruiting

  • Two Bridges Research & Development Clinic

    Chertsey, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.